Literature DB >> 7694429

Maternal serum screening for neural tube defects and fetal chromosome abnormalities.

N C Rose1, M T Mennuti.   

Abstract

Second-trimester maternal serum screening is a noninvasive means of identifying pregnant women at an increased risk for various conditions including a fetus with open spina bifida, fetal Down syndrome, trisomy 18, multiple gestation, and adverse pregnancy outcome. Combinations of several different markers are available for screening. These include alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol. In this review, we discuss the benefits and limitations of the screening tests and the suggested protocols for the care of patients.

Entities:  

Keywords:  Genetics and Reproduction; Health Care and Public Health

Mesh：

Substances：

Year:  1993        PMID： 7694429      PMCID： PMC1011344     

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


  29 in total

1.  Prenatal screening for Down's syndrome with use of maternal serum markers.

Authors:  J E Haddow; G E Palomaki; G J Knight; J Williams; A Pulkkinen; J A Canick; D N Saller; G B Bowers
Journal:  N Engl J Med       Date:  1992-08-27       Impact factor: 91.245

2.  Decisions following the intrauterine diagnosis of sex chromosome aneuploidy.

Authors:  A Robinson; B G Bender; M G Linden
Journal:  Am J Med Genet       Date:  1989-12

3.  Prenatal screening for trisomy 18 in the second trimester.

Authors:  J A Canick; G E Palomaki; R Osathanondh
Journal:  Prenat Diagn       Date:  1990-08       Impact factor: 3.050

4.  A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.

Authors:  E Y Cheng; D A Luthy; A M Zebelman; M A Williams; R E Lieppman; D E Hickok
Journal:  Obstet Gynecol       Date:  1993-01       Impact factor: 7.661

5.  Prenatal diagnosis of spina bifida and anencephaly by maternal serum-alpha-fetoprotein measurement. A controlled study.

Authors:  N J Wald; D J Brock; J Bonnar
Journal:  Lancet       Date:  1974-04-27       Impact factor: 79.321

6.  Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida.

Authors:  D J Brock; R G Sutcliffe
Journal:  Lancet       Date:  1972-07-29       Impact factor: 79.321

7.  Absence of need for amniocentesis in patients with elevated levels of maternal serum alpha-fetoprotein and normal ultrasonographic examinations.

Authors:  A S Nadel; J K Green; L B Holmes; F D Frigoletto; B R Benacerraf
Journal:  N Engl J Med       Date:  1990-08-30       Impact factor: 91.245

8.  Prenatal screening for Down syndrome with maternal serum human chorionic gonadotropin levels.

Authors:  E Petrocik; E R Wassman; J C Kelly
Journal:  Am J Obstet Gynecol       Date:  1989-11       Impact factor: 8.661

9.  Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.

Authors:  O P Phillips; S Elias; L P Shulman; R N Andersen; C D Morgan; J L Simpson
Journal:  Obstet Gynecol       Date:  1992-09       Impact factor: 7.661

10.  Cesarean section before the onset of labor and subsequent motor function in infants with meningomyelocele diagnosed antenatally.

Authors:  D A Luthy; T Wardinsky; D B Shurtleff; K A Hollenbach; D E Hickok; D A Nyberg; T J Benedetti
Journal:  N Engl J Med       Date:  1991-03-07       Impact factor: 91.245
View more
  2 in total

Review 1.  The implications of exosomes in pregnancy: emerging as new diagnostic markers and therapeutics targets.

Authors:  Roya Mahdavi; Zahra Akbari Jonoush; Mehri Ghafourian; Mahvash Sadeghi; Nooshin Ghadiri; Maryam Farzaneh; Abdolah Mousavi Salehi
Journal:  Cell Commun Signal       Date:  2022-04-12       Impact factor: 5.712

2.  Clinical utility of folate-containing oral contraceptives.

Authors:  Zohra S Lassi; Zulfiqar A Bhutta
Journal:  Int J Womens Health       Date:  2012-04-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.